Navigation Links
InterMune Presents Research on ITMN-191 in Hepatitis C at EASL,Annual Meeting

tors and interferons, and discovering important insights into possible treatment regimens for chronic hepatitis C," said Lawrence M. Blatt, Ph.D., Chief Scientific Officer of InterMune. "We anticipate that treatment regimens will involve multiple agents, and we are hopeful that these combinations will lead to improved, sustained virologic responses for patients who are in need of more optimal therapies."

The third presentation concerned NS3 sequence variations in HCV replicons after exposure to ITMN-191 at clinically relevant concentrations. The NS3 sequence was found to undergo dynamic changes when exposed to increasing concentrations of ITMN-191. As was seen in previous work, substitution at position 168 of NS3 appears to be fundamental to resistance but alone is not sufficient for HCV replicon persistence at all ITMN-191 concentrations achieved in the liver of animal species following oral dosing. This suggests that the genetic barrier to resistance in patients following clinical dosing of ITMN-191 may be significant dependent upon human liver exposure.

InterMune currently is conducting a Phase 1a clinical study of ITMN-191 for the treatment of chronic HCV. Preclinical toxicology and pharmacokinetic studies in multiple species demonstrated that ITMN-191 has a favorable toxicology profile, significant liver exposure, high in vitro potency and specificity, and an advantageous cross-resistance profile, including considerable effectiveness against variants of the NS3/4A protease that are resistant to other HCV protease inhibitors currently in development. The preclinical pharmacokinetic results support the exploration of twice-daily oral dosing. InterMune and Roche have a collaboration agreement for the research, development and commercialization of ITMN-191 (referred to as R7227 within the Roche research and development programs) and second-generation HCV protease inhibitor compounds.

According to the Centers for Disease Control and Prevention (
'"/>




Page: 1 2 3 4

Related medicine technology :

1. InterMune Presents Research on ITMN-191 in Hepatitis C at Digestive Disease Week Meeting
2. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
3. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
4. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
5. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
6. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
7. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
8. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
9. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
10. Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Associations Annual Meeting
11. DiObex Presents Phase 2a Data of DIO-902 Demonstrating Trends of Improved Glycemic Control and Significant Reductions of LDL-Cholesterol and C-Reactive Protein
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: InterMune Presents Research ITMN Hepatitis EASL Annual Meeting
(Date:1/15/2014)... , Jan. 15, 2014  Valeant Pharmaceuticals International, Inc. ... that the applicable waiting period under the Hart-Scott-Rodino Antitrust ... previously announced tender offer by its indirect wholly-owned subsidiary, ... shares of common stock of Solta Medical, Inc. (NASDAQ: ...
(Date:1/15/2014)... , Jan. 15, 2014  A novel wearable injector slightly larger ... painless for patients to self-inject prescription drugs in the large ... cancer, blood diseases, autoimmune deficiencies, and genetic disorders.  ... to $220B by 2018, according to analysts.   Many of these ...
(Date:1/14/2014)... , Jan. 14, 2014 The Brandeis Medical Center, led ... a premier and affordable laser tattoo removal experience with ... Brandeis, focus is in providing high quality cosmetic services with cutting ... " Southern California has seen a ...
Breaking Medicine Technology:Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2Beverly Hills Physician Features Tattoo Removal with the Astanza Duality Laser, Offers $99 Special 2
... , NEW YORK, Dec. 9 MR, CT, PET - we,ve ... these hi-tech imaging scans? Here,s more on what questions you ... hood with a medical scan. , Listen to this report from ... a division of The NewsMarket. Registered journalists can access video, ...
... , , , INDIANAPOLIS, Dec. 9 ... leading provider of managed voice, Internet and data networking solutions ... that Indiana Blood Center has selected the company to provide ... 11 locations located throughout Indiana. Indiana Blood Center will also ...
Cached Medicine Technology:Indiana Blood Center Taps tw telecom for Data, Internet and IP Telephony Services 2
(Date:7/9/2014)... low back pain are not linked to weather conditions ... precipitation. Findings published in Arthritis Care & Research ... (ACR), indicate that the risk of low back pain ... but was not clinically significant. , According to ... back pain at some point in their life, making ...
(Date:7/9/2014)... in almost all types of cancer sends the protein ... fuel a tumour,s uncontrolled growth, new research suggests. , ... a molecular trigger responsible for ratcheting up activity of ... makes the building blocks cancer cells need to keep ... called SREBP, controls the flow of messages to the ...
(Date:7/9/2014)... Researchers have found that fecal transplantation is effective and ... patients. This is the result of a study led ... for Women,s Gastrointestinal Medicine at The Women,s Medicine Collaborative. ... in advance of print in the American Journal ... C. diff , has increased to epidemic proportions ...
(Date:7/9/2014)... 2014 There has been a sharp increase in ... Center using MyChart, the online, interactive service that allows ... their healthcare providers, schedule appointments, and renew prescriptions. , ... using MyChart each year increased five-fold, while ... than 10-fold, according to a study by Dr. ...
(Date:7/9/2014)... of Allergy and Infectious Diseases (NIAID), part of ... early-stage clinical trial of CRS3123, an investigational oral ... ( C. difficile ) infection. CRS3123 (previously known ... C. difficile growth while sparing normal intestinal bacteria. ... to 30 healthy men and women ages 18 ...
Breaking Medicine News(10 mins):Health News:Low back pain? Don't blame the weather 2Health News:Signal may send cancer's cellular factories into overdrive 2Health News:Women's Medicine Collaborative examines safety of fecal transplant to treat C. difficile 2Health News:MyChart use skyrocketing among cancer patients, UT Southwestern study finds 2Health News:MyChart use skyrocketing among cancer patients, UT Southwestern study finds 3Health News:NIH launches Phase I clinical trial of novel drug to treat Clostridium difficile infection 2
... new health reform in China have been released after ... the most important policies ,The National Essential Drug System,. ... high cost of drugs in China through a government-initiated ... that cover a wide range of diseases and meet ...
... today a partnership with Medical Hair Restoration. , ... ... LLC, an online lead generation company, announced today a partnership with ... property, USHairReplacement.com, we wanted to partner with one of the industry ...
... ScarArt is a specially designed temporary tattoo to fit horizontal tummy tuck ... It is waterproof, smear proof and was designed to last 1-3 days. ... ... TX (PRWEB) May 21, 2009 -- ScarArt, an innovative new company specializing ...
... source of information on multiple sclerosis medications and the financial ... ... 21, 2009 -- NeedyMeds, a national nonprofit, added a new resource page ... The page is a multiple sclerosis-specific source of help for those looking ...
... OAK BROOK, Ill., May 21 The University HealthSystem ... 3-year agreement with Mzinga, Inc. for on-demand learning solutions. ... and became effective on March 1, 2009, positions Mzinga ... UHC member hospitals throughout the United States, building on ...
... be associated with obesity. But a new study published ... that the disorder is widely undiagnosed among obese individuals with ... symptoms, but were never diagnosed. , For those with untreated ... existing research shows that it can also mean an increased ...
Cached Medicine News:Health News:Frost & Sullivan Looks at the Influence of China's New Health Reform on the Pharmaceutical Market 2Health News:Frost & Sullivan Looks at the Influence of China's New Health Reform on the Pharmaceutical Market 3Health News:The Oro Organization, LLC Partners with Medical Hair Restoration to Launch New Website USHairReplacement.com 2Health News:ScarArt -Creatively Camouflage Abdominal Scars 2Health News:New Source of Information on Multiple Sclerosis Medications 2Health News:University HealthSystem Consortium Selects Mzinga for On-Demand Learning Services 2Health News:University HealthSystem Consortium Selects Mzinga for On-Demand Learning Services 3Health News:More than a bad night's sleep 2
BD Vacutainer Citrate Tubes with 3.2% buffered sodium citrate solution are used for routine coagulation studies....
... Cross-match tubes are available ... serum tube contains a clotting ... cross-match tests where serum is ... EDTA cross-match tube is suitable ...
... tubes are available in two ... contains a clotting activator and ... where serum is required for ... tube is suitable where the ...
Inquire...
Medicine Products: